Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-70 years, male or female;~2. Subject meets one of the following conditions:~1) Subject with a history of gout has a serum uric acid ≥480μmol/l at screening; 2) Subject with a history of hyperuricemia has a serum uric acid ≥540μmol/l at screening, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3) Subject with a history of hyperuricemia has a serum uric acid≥480μmol/l at screening, on stable treatment for hypertensive, hyperlipidemia or diabetes for at least 3 month, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3. 18kg/m2≤ BMI ≤32kg/m2.~Exclusion Criteria:~1. Subject who is pregnant or breastfeeding;~2. Alanine aminotransferase or Aspartate aminotransferase or total bilirubin\>1.5 upper normal limit;~3. Estimated glomerular filtration rate (MDRD formula) ˂60ml/min;~4. HbA1c˃8%;~5. Subject with known hypersensitivity or allergy to SHR4640 or any component of SHR4640;~6. Subject with a history of malignancy;~7. Subject with a history of urolithiasis, or positive findings on ultrasound examination at screen~8. Subject within the last 3months has: myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemia attack;~9. Subject has acute gout flares within 2 weeks before randomization;~10. Subject who is taking any other urate-lowering medication (allopurinol, febuxostat, probenecid and benzbromarone) that is indicated within 2 weeks before randomization and can not stop during the study;~11. Subject who is taking more than 100mg once daily or unstable dosage aspirin within 2 weeks before randomization and can not stop during the study;~12. Subject who is taking any diuretic within 2 weeks before randomization and can not stop during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo for 5 weeks
- 2.5mg SHR4640 (Type: EXPERIMENTAL): SHR4640 for 5 weeks
- 5mg SHR4640 (Type: EXPERIMENTAL): SHR4640 for 5 weeks
- 10mg SHR4640 (Type: EXPERIMENTAL): SHR4640 for 5 weeks
- 50mg benzbromarone (Type: ACTIVE_COMPARATOR): Benzbromarone for 5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).